NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$39.01 -1.64 (-4.03 %)
(As of 12/13/2018 04:00 PM ET)
Previous Close$40.65
Today's Range$38.75 - $40.89
52-Week Range$38.50 - $74.75
Volume614,926 shs
Average Volume424,735 shs
Market Capitalization$1.84 billion
P/E Ratio-11.58
Dividend YieldN/A
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Current SymbolNASDAQ:AERI
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio7.05
Quick Ratio6.89


Trailing P/E Ratio-11.58
Forward P/E Ratio-7.12
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.60 per share
Price / Book10.84


EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-106.13%
Return on Assets-65.99%


Outstanding Shares45,450,000
Market Cap$1.84 billion

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its quarterly earnings data on Tuesday, November, 6th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.33) by $0.40. The company earned $7.30 million during the quarter, compared to the consensus estimate of $5.63 million. View Aerie Pharmaceuticals' Earnings History.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Aerie Pharmaceuticals.

What price target have analysts set for AERI?

11 Wall Street analysts have issued twelve-month price targets for Aerie Pharmaceuticals' stock. Their forecasts range from $64.00 to $105.00. On average, they expect Aerie Pharmaceuticals' share price to reach $81.00 in the next year. This suggests a possible upside of 107.6% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.

What is the consensus analysts' recommendation for Aerie Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We note that one or two weeks of data can have a meaningful impact on our total 2018 projections and we used what we believe are conservative assumptions. We believe there could be upside to our current estimate and we believe the risk of Aerie not delivering on its 2018 sales guidance of $20-30 mil is low." (11/27/2018)
  • 2. According to Zacks Investment Research, "The FDA approval of Aerie’s lead drug, Rhopressa is a significant boost for the company. The solid uptake in prescription volumes post launch should propel sales as glaucoma is one of the largest segments in the global ophthalmic market. Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie recently submitted its NDA for Roclatan to the FDA and expects a review period of ten months. A tentative approval will boost the growth prospects. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan and Vyzulta among others. Hence, Rhopressa will face a tough time in gaining market share due to competition from these products. Shares have underperformed the industry in the  year so far." (10/10/2018)
  • 3. Cantor Fitzgerald analysts commented, "We rate Aerie Pharmaceuticals Overweight. AERI commercializes and develops once- daily eye drops Rhopressa and Roclatan, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our price target is $86/share." (10/2/2018)
  • 4. Canaccord Genuity analysts commented, "We hosted Aerie CFO a fireside chat this afternoon at the Canaccord Genuity Growth Conference. Aerie is an ophthalmology company that recently launched Rhopressa, the first new class of glaucoma drugs in over twenty years. In addition to Rhopressa, Aerie plans to commercialize Roclatan, a combination of Rhopressa and latanoprost, the leading glaucoma therapy in the US market. Beyond glaucoma, Aerie is exploring the use of ROCK inhibitors in back-of-the-eye conditions like wet AMD and could explore opportunities to utilize ROCK inhibitors outside of ophthalmology. Rhopressa tracking well with strong user feedback. Launched earlier this year, Rhopressa is already gaining traction with ophthalmologists and patients, and Aerie is pleased with the current uptake trajectory." (8/10/2018)

Has Aerie Pharmaceuticals been receiving favorable news coverage?

News articles about AERI stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 65)
  • Mr. Thomas A. Mitro, Pres & COO (Age 60)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
  • Ms. Jessica Crespo CPA, Director of Accounting

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.55%), Vanguard Group Inc (8.55%), BlackRock Inc. (6.91%), Partner Fund Management L.P. (4.97%), Jennison Associates LLC (3.07%) and HealthCor Management L.P. (2.27%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Geoffrey M Duyk, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Which institutional investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., HealthCor Management L.P., FMR LLC, Morgan Stanley, Pictet Asset Management Ltd., Marshall Wace North America L.P., Jane Street Group LLC and Thrivent Financial for Lutherans. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.

Which institutional investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Provident Investment Management Inc., Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Kornitzer Capital Management Inc. KS, BlackRock Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $39.01.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $1.84 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  858
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel